BioSpace News Archive

Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its wholly-owned CLIA/CAP laboratory Provista Diagnostics has entered into a new reference lab agreement with an Atlanta-based CLIA laboratory (the “New Client”).

Viewpoint Molecular Targeting, Inc. announced it has entered into a Memorandum of Understanding with The National Nuclear Laboratory to explore avenues to supply Pb-212 to researchers, and possibly clinicians, in the United Kingdom and Europe, using Viewpoint’s proprietary isotope generator, VMT-

Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced financial results for the third quarter ended September 30, 2021.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) reports that recent research analysis provides additional support for anti-oxidation structure/function claims of VINIA®.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today provided a joint business update for the companies and discussed preliminary financial results for the six and nine months ended September 30, 2021.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that in connection with the appointment of Kristen Harrington-Smith as ImmunoGen’s Senior Vice President and Chief Commercial Officer, the Company granted to Ms. Harrington-Smith awards of non-qualified stock options and restricted stock units, under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

The partnership establishes a framework and strategic relationship to assess NHS organizational readiness for ketamine-assisted psychotherapy.

Novoron Bioscience, a San Diego-based biotechnology company developing first-in-class therapies to reverse central nervous system damage, announced that they secured a $3 million Seed investment from Two Bear Capital.